Having been short of good news, Telix says the first stage of its phase III prostate cancer therapeutic trial has hit its desired safety and dosage goals. Telix today said the candidate, TLX591-Tx , ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results